BIOCYTOGEN-B (02315) rose more than 5% during the trading session. As of the time of writing, the stock was up 3.26%, currently trading at HKD 35.50, with a turnover of HKD 31.2655 million.
The Shanghai Stock Exchange and the Shenzhen Stock Exchange recently announced that BIOCYTOGEN will be included in the Stock Connect program list, effective from December 24, 2025. This move marks another significant milestone following the company's establishment of a dual capital market platform spanning both A-shares and H-shares, as its H-share channel is now fully open to mainland investors.
Huafu Securities previously noted in a research report that the company's "Thousand Mice Ten Thousand Antibodies" platform is beginning to deliver results, with antibody licensing driving an earnings surge. Considering the company's high growth potential and strong business moat, its solid foundation in preclinical animal and pharmacodynamic evaluation, and its antibody development business gradually entering a phase of performance realization—coupled with the potential of its new drug pipeline—the firm initiated coverage with a "Buy" rating.
